MLYS

Mineralys is a pre-revenue clinical-stage biopharma whose entire value rests on one asset, lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled/resistant hypertension. The story is unusually de-risked for its stage: the company completed two pivotal trials (Phase 3 Launch-HTN, Phase 2 Advance-HTN) that the MD&A says showed 'robust, durable, and clinically meaningful' systolic BP reductions with a favorable safety profile, results strong enough to be published in JAMA and NEJM and to earn JAMA 'Research of the Year' recognition. The NDA was submitted in December 2025, the FDA accepted it, and a PDUFA target action date of December 22, 2026 is set. The addressable market is large — ~30M+ treated hypertensives not at goal, with dysregulated aldosterone implicated in ~30% of uncontrolled/resistant cases — and Explore-CKD/Explore-OSA readouts hint at label-expansion optionality.

The balance sheet is the other half of the bull case and is genuinely strong for a biotech: $647M stockholders' equity against just $15.1M current liabilities, and $661M of current assets versus a roughly $142M annual operating cash burn. Even though headline cash is only $173M, the bulk of current assets is almost certainly marketable securities, implying multiple years of runway that comfortably funds the company through the PDUFA date and into a potential launch. That funding security is what separates this from a typical 'avoid' clinical-stage name. The net loss actually narrowed YoY (-$155M vs -$178M) and R&D fell 22% as the pivotal program wrapped.